HomeProductsDenufosol
Chemical structure of CAS 211448-85-0

Denufosol

CAS No.211448-85-0
MDL No.N/A
MFC18H27N5O21P4
MW773.30
InChI KeyFPNPSEMJLALQSA-MIYUEGBISA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.211448-85-0
Product NameDenufosol

Biological Targets

P2RY2

Associated Conditions

retinal detachment·cystic fibrosis·macular retinal edema·Rhinitis, Allergic, Perennial
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

American journal of respiratory and critical care medicine • Vol. 176, Issue 4 • 2007
PMID: 17446337DOI: 10.1164/rccm.200608-1238OC

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

The Journal of pharmacology and experimental therapeutics • Vol. 302, Issue 3 • 2002
PMID: 12183642DOI: 10.1124/jpet.102.035485

The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.

Investigative ophthalmology & visual science • Vol. 43, Issue 11 • 2002
PMID: 12407168

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

Advanced drug delivery reviews • Vol. 54, Issue 11 • 2002
PMID: 12458155DOI: 10.1016/s0169-409x(02)00154-0

Documentation

Similar Products